We found that ESR1 mutations showed a trend towards higher prevalence in patients with tumours classified as luminal A by PAM50 compared with luminal B (41.4 versus 31.8%), as well as in patients with tumours harbouring PIK3CA mutations (44.4%). Here, ESR1 is linked to neoplasm.